Sirio Pharma Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 5/6

Sirio Pharma yıllık ortalama 10% oranında kazançlarını artırırken, Personal Products sektöründe kazançlar growing at 7.9% annual. Gelirler growing yılda ortalama 19.1% oranında artmaktadır. Sirio Pharma'in özkaynak karlılığı 11.4% ve net marjı 8.1%'dir.

Anahtar bilgiler

10.0%

Kazanç büyüme oranı

7.2%

EPS büyüme oranı

Personal Products Sektör Büyümesi	7.8%
Gelir büyüme oranı	19.1%
Özkaynak getirisi	11.4%
Net Marj	8.1%
Son Kazanç Güncellemesi	30 Sep 2024

Yakın geçmiş performans güncellemeleri

Recent updates

Gelir ve Gider Dağılımı

Sirio Pharma nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.

Kazanç ve Gelir Geçmişi

XSEC:300791 Gelir, gider ve kazançlar (CNY Millions )
Tarih	Gelir	Kazançlar	G+A Giderleri	Ar-Ge Giderleri
30 Sep 24	4,128	336	725	134
30 Jun 24	4,028	334	698	131
31 Mar 24	3,831	315	658	119
31 Dec 23	3,582	281	627	110
30 Sep 23	3,222	221	564	95
30 Jun 23	2,941	204	517	88
31 Mar 23	2,788	227	485	84
01 Jan 23	2,507	212	432	81
30 Sep 22	2,409	208	408	85
30 Jun 22	2,315	196	398	82
31 Mar 22	2,283	189	377	84
31 Dec 21	2,369	232	386	83
30 Sep 21	2,361	272	350	74
30 Jun 21	2,316	279	335	74
31 Mar 21	2,216	265	336	71
31 Dec 20	2,067	257	310	65
30 Sep 20	1,865	209	327	68
30 Jun 20	1,710	178	312	66
31 Mar 20	1,554	156	285	62
31 Dec 19	1,580	143	279	66
30 Sep 19	1,625	186	254	66
31 Dec 18	1,595	203	238	62
31 Dec 17	1,330	104	225	46
31 Dec 16	786	704	151	41

Kaliteli Kazançlar: 300791 yüksek kaliteli kazançlar sağlıyor.

Büyüyen Kar Marjı: 300791 'nin mevcut net kar marjları (8.1%) geçen yılın (6.9%) sinden daha yüksektir.

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: 300791 şirketinin kazancı son 5 yılda yılda 10% oranında arttı.

Büyüme Hızlandırma: 300791 'un son bir yıldaki kazanç büyümesi ( 51.7% ) 5 yıllık ortalamasını (yıllık 10% ) aşıyor.

Kazançlar vs. Sektör: 300791 geçen yılki kazanç büyümesi ( 51.7% ) Personal Products sektörünün -6% değerini aştı.

Özkaynak Getirisi

Yüksek ROE: 300791 'nin Özsermaye Getirisi ( 11.4% ) düşük olarak değerlendiriliyor.

Sirio Pharma Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 5/6

Anahtar bilgiler

Yakın geçmiş performans güncellemeleri

Third quarter 2024 earnings released: EPS: CN¥1.22 (vs CN¥0.36 in 3Q 2023)

Sirio Pharma Co., Ltd. to Report Q3, 2024 Results on Oct 24, 2024

Second quarter 2024 earnings released: EPS: CN¥0.74 (vs CN¥0.30 in 2Q 2023)

Sirio Pharma Co., Ltd. to Report First Half, 2024 Results on Aug 23, 2024

First quarter 2024 earnings released: EPS: CN¥0.35 (vs CN¥0.16 in 1Q 2023)

Sirio Pharma Co., Ltd. to Report Q1, 2024 Results on Apr 27, 2024

Recent updates

Third quarter 2024 earnings released: EPS: CN¥1.22 (vs CN¥0.36 in 3Q 2023)

Investor sentiment deteriorates as stock falls 16%

Investor sentiment improves as stock rises 29%

Sirio Pharma Co., Ltd. to Report Q3, 2024 Results on Oct 24, 2024

Second quarter 2024 earnings released: EPS: CN¥0.74 (vs CN¥0.30 in 2Q 2023)

Now 21% overvalued

Now 21% overvalued

Sirio Pharma Co., Ltd. to Report First Half, 2024 Results on Aug 23, 2024

First quarter 2024 earnings released: EPS: CN¥0.35 (vs CN¥0.16 in 1Q 2023)

Sirio Pharma Co., Ltd. to Report Q1, 2024 Results on Apr 27, 2024

Sirio Pharma Co., Ltd. to Report Fiscal Year 2023 Results on Apr 22, 2024

Third quarter 2023 earnings released: EPS: CN¥0.47 (vs CN¥0.37 in 3Q 2022)

Investor sentiment improves as stock rises 17%

Second quarter 2023 earnings released: EPS: CN¥0.40 (vs CN¥0.54 in 2Q 2022)

Sirio Pharma Co., Ltd. to Report First Half, 2023 Results on Aug 25, 2023

Sirio Pharma Co., Ltd. Announces Implementation of Cash Dividend for the Year 2022, Payable on June 07, 2023

Full year 2022 earnings released: EPS: CN¥1.18 (vs CN¥1.29 in FY 2021)

Investor sentiment improved over the past week

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: CN¥0.37 (vs CN¥0.30 in 3Q 2021)

Investor sentiment improved over the past week

Second quarter 2022 earnings released: EPS: CN¥0.54 (vs CN¥0.49 in 2Q 2021)

Now 23% undervalued

Now 20% undervalued

Sirio Pharma Co., Ltd. announced that it expects to receive CNY 1.35 billion in funding

Investor sentiment improved over the past week

Now 21% undervalued after recent price drop

Sirio Pharma Co., Ltd. Announces Final Profit Distribution Plan for 2021 on A Shares, Payable on 23 May 2022

Less than half of directors are independent

Sirio Pharma Co., Ltd., Annual General Meeting, May 05, 2022

First quarter 2022 earnings released: EPS: CN¥0.08 (vs CN¥0.32 in 1Q 2021)

Now 23% undervalued after recent price drop

Sirio Pharma Co., Ltd. Announces the Profit Distribution Proposal for 2021

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Third quarter 2021 earnings released: EPS CN¥0.30 (vs CN¥0.34 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.49 (vs CN¥0.41 in 2Q 2020)

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Sirio Pharma Co., Ltd. Approves Final Divided for 2020

Sirio Pharma Co., Ltd. Proposes Final Dividend for the Year 2020

Full year 2020 earnings released: EPS CN¥2.14 (vs CN¥1.46 in FY 2019)

New 90-day low: CN¥83.31

New 90-day high: CN¥113

Investor sentiment improved over the past week

New 90-day low: CN¥84.38

New 90-day low: CN¥86.60

Third quarter earnings released

Market bids up stock over the past week

New 90-day high - CN¥116

Earnings released

Sirio Pharma Co., Ltd. to Report First Half, 2020 Results on Aug 25, 2020

New 90-day high - CN¥99.91

Sirio Pharma Co., Ltd. announced a financing transaction

Gelir ve Gider Dağılımı

Kazanç ve Gelir Geçmişi

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Özkaynak Getirisi

Varlık Getirisi

Kullanılan Sermaye Getirisi

Geçmişte güçlü performans gösteren şirketleri keşfedin